These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 18484235

  • 1. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis.
    Comabella M, Julià E, Tintoré M, Brieva L, Téllez N, Río J, López C, Rovira A, Montalban X.
    J Neurol; 2008 Aug; 255(8):1136-41. PubMed ID: 18484235
    [Abstract] [Full Text] [Related]

  • 2. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.
    Rieckmann P, Kruse N, Nagelkerken L, Beckmann K, Miller D, Polman C, Dahlke F, Toyka KV, Hartung HP, Stürzebecher S.
    J Neurol; 2005 May; 252(5):526-33. PubMed ID: 15895275
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [Abstract] [Full Text] [Related]

  • 4. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
    Schmid I, Schmitt M, Streiter M, Meilbeck R, Haas RJ, Stachel DK.
    Eur J Med Res; 2005 Nov 16; 10(11):457-61. PubMed ID: 16354598
    [Abstract] [Full Text] [Related]

  • 5. Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients.
    Bahner D, Klucke C, Kitze B, Elitok E, Bogumil T, Dressel A, Tumani H, Weber F, Poser S, Bitsch A.
    Neurosci Lett; 2002 Jun 28; 326(2):125-8. PubMed ID: 12057844
    [Abstract] [Full Text] [Related]

  • 6. Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma.
    Yoshida S, Hashimoto S, Nakayama T, Kobayashi T, Koizumi A, Horie T.
    Clin Exp Immunol; 1996 Oct 28; 106(1):73-8. PubMed ID: 8870701
    [Abstract] [Full Text] [Related]

  • 7. Soluble TNF-alpha receptor and IL-1 receptor antagonist elevation in BAL in active pulmonary TB.
    Tsao TC, Li L, Hsieh M, Liao S, Chang KS.
    Eur Respir J; 1999 Sep 28; 14(3):490-5. PubMed ID: 10543265
    [Abstract] [Full Text] [Related]

  • 8. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
    Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F, European Study Group in Interferon beta-1b in Secondary-Progressive MS.
    Neurology; 2001 Dec 11; 57(11):1969-75. PubMed ID: 11739811
    [Abstract] [Full Text] [Related]

  • 9. Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis.
    Fissolo N, Cantó E, Vidal-Jordana A, Castilló J, Montalban X, Comabella M.
    J Neuroimmunol; 2014 Jun 15; 271(1-2):56-9. PubMed ID: 24794503
    [Abstract] [Full Text] [Related]

  • 10. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity.
    Laske C, Oschmann P, Tofighi J, Kuehne SB, Diehl H, Bregenzer T, Kraus J, Bauer R, Chatzimanolis N, Kern A, Traupe H, Kaps M.
    Acta Neurol Scand; 2001 Feb 15; 103(2):105-13. PubMed ID: 11227128
    [Abstract] [Full Text] [Related]

  • 11. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS.
    Neurology; 2004 Nov 23; 63(10):1788-95. PubMed ID: 15557491
    [Abstract] [Full Text] [Related]

  • 12. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.
    Tsao TC, Hong Jh, Li LF, Hsieh MJ, Liao SK, Chang KS.
    Chest; 2000 Jan 23; 117(1):103-9. PubMed ID: 10631206
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b.
    Laske C, Oschmann P, Tofighi J, Kühne BS, Diehl H, Bregenzer T, Kraus J, Chatzimanolis N, Bauer R, Traupe H, Kaps M.
    Eur Neurol; 2001 Jan 23; 46(4):210-4. PubMed ID: 11721129
    [Abstract] [Full Text] [Related]

  • 14. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ.
    J Neurol; 2003 Sep 23; 250(9):1037-43. PubMed ID: 14504963
    [Abstract] [Full Text] [Related]

  • 15. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
    Tesar V, Jirsa M, Zima T, Kalousová M, Bartunková J, Stejskalová A, Dostál C, Zabka J.
    Med Sci Monit; 2002 Jan 23; 8(1):BR24-9. PubMed ID: 11782670
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K, Mannitol Formulation Study Group.
    J Int Med Res; 2006 Jan 23; 34(1):1-12. PubMed ID: 16604818
    [Abstract] [Full Text] [Related]

  • 17. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder.
    Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, Agartz I, Aukrust P, Andreassen OA.
    Schizophr Res; 2013 Apr 23; 145(1-3):36-42. PubMed ID: 23403415
    [Abstract] [Full Text] [Related]

  • 18. The enhanced plasma levels of soluble tumor necrosis factor receptors (sTNF-R1; sTNF-R2) and interleukin-10 (IL-10) in patients suffering from chronic heart failure are reversed in patients treated with beta-adrenoceptor antagonist.
    Loppnow H, Werdan K, Werner C.
    Auton Autacoid Pharmacol; 2002 Apr 23; 22(2):83-92. PubMed ID: 12568125
    [Abstract] [Full Text] [Related]

  • 19. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
    Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH.
    Brain; 2000 Nov 23; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
    [Abstract] [Full Text] [Related]

  • 20. MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients.
    Millonig A, Dressel A, Bahner D, Bitsch A, Bogumil T, Elitok E, Kitze B, Tumani H, Weber F, Gneiss C, Deisenhammer F.
    Eur J Neurol; 2008 Aug 23; 15(8):822-6. PubMed ID: 18549400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.